Trial Profile
Immune Response Induced by Different Manufacturers of Influenza Vaccines.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 29 Apr 2016 Status changed from active, no longer recruiting to completed.
- 21 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.